Hard to believe?, page-29

What a Gas, IMO HerVaxx alone justifies a much higher sp as it is superior to all what's on the market.
From my correspondences with the Prof I can tell you that IMU was interested in some IP that was developed after B-vax and is a supplement to what IMU got. B-vax was developed years before HerVaxx and Key-Vax is the newest. The progress is so fast, any new VAX will be much more effective than the previous one. Focus is on HerVaxx and Key-Vax but data from B- VAX will still be valuable. In science even a failure is a gain of knowledge,of course not in the ASX world.
Another important fact is that IMU has built up a network of universities worldwide researching for IMU to tailor peptides for a variety of cancers.  No accident that the SAB is growing as IMU is like becoming a vax-factory, which they have stated a few times on their website and presos. We just need the first VAX successfully to get through the trials and the mass roll out can start. A cancer free world in 10 years is more reality then a dream.

GLTA